Qualitative or quantitative defects of protein O-mannose beta1,2N-acetylglucosaminyltransferase

Qualitative or quantitative defects of protein O-mannose beta-1,2-N-acetylglucosaminyltransferase (POMGnT1) refer to a group of disorders caused by mutations in the POMGNT1 gene, which encodes an enzyme critical for the proper glycosylation (sugar modification) of alpha-dystroglycan. Alpha-dystroglycan is a key protein that links the interior of muscle and brain cells to the surrounding extracellular matrix. When POMGnT1 is deficient or dysfunctional, alpha-dystroglycan is hypoglycosylated, leading to a category of conditions known as dystroglycanopathies. These disorders primarily affect the muscular, neurological, and ocular systems. The clinical spectrum associated with POMGNT1 defects ranges from severe forms such as muscle-eye-brain disease (MEB disease, also known as Walker-Warburg-like syndrome or Santavuori disease) to milder limb-girdle muscular dystrophy presentations. In the more severe forms, patients typically present at birth or in early infancy with congenital muscular dystrophy, structural brain abnormalities (including cobblestone lissencephaly, cerebellar malformations, and hydrocephalus), severe intellectual disability, seizures, and eye abnormalities (such as severe myopia, retinal dysplasia, glaucoma, and cataracts). Milder phenotypes may present later with progressive muscle weakness, variable cognitive impairment, and less pronounced eye involvement. There is currently no cure for POMGNT1-related dystroglycanopathies. Treatment is supportive and multidisciplinary, involving neurologists, ophthalmologists, orthopedic specialists, and physical therapists. Management focuses on seizure control, physical rehabilitation, surgical correction of eye or orthopedic complications, and nutritional support. Genetic counseling is recommended for affected families. Research into gene therapy and pharmacological approaches to restore dystroglycan glycosylation is ongoing but remains in early stages.

Common questions about Qualitative or quantitative defects of protein O-mannose beta1,2N-acetylglucosaminyltransferase